根据甲状腺功能评估心房颤动筛查的效果:随机LOOP研究的事后分析
该研究为随机LOOP研究的事后分析,按基线促甲状腺激素(TSH)水平分层,评估植入式循环记录仪筛查心房颤动(AF)并据此抗凝与常规诊疗相比对卒中或系统性栓塞(SE)的影响。在低TSH三分位组,筛查与主要结局风险降低相关(HR 0.52,95%CI 0.30-0.90;P=.02),较高TSH组未见此效应(交互作用P=.03)。作者认为TSH或可作为提示AF筛查获益的标志物,但结果属探索性,需进一步研究。
要点
- 在低TSH三分位组,AF筛查与主要结局风险降低相关(HR 0.52,95%CI 0.30-0.90)。
- 较高TSH组未见筛查对主要结局的效应(交互作用P=.03)。
- 各TSH三分位组中ILR筛查的AF检出率均约为常规诊疗的三倍(交互作用P=.44)。
核心结论
- 在低TSH参与者中,AF筛查及后续治疗与卒中风险降低相关,但筛查检出率在各TSH水平间相似。
- TSH或可作为标志物提示AF筛查的获益与过度诊断和过度治疗之间的权衡。
- 作者指出这些发现应视为探索性,需进一步研究。
研究设计与样本
- 随机LOOP研究的事后分析,按基线TSH水平进行分层分析。
- 6004例试验参与者中6003例有TSH测量值,1500例随机接受植入式循环记录仪(ILR)筛查AF并在检出后抗凝,4503例接受常规诊疗。
- 平均年龄74.7±4.1岁,女性2836例(47%)。
主要发现
- 各TSH三分位组中,ILR筛查的AF检出率约为常规诊疗的三倍(校正交互作用P=.44)。
- 第一三分位组中,筛查与主要结局风险降低相关(HR 0.52,95%CI 0.30-0.90;P=.02)。
- 第一三分位组中,筛查与卒中、SE或心血管死亡复合结局风险降低相关(HR 0.54,95%CI 0.34-0.84;P=.006)。
- 较高TSH组中未观察到筛查对主要结局及卒中、SE或心血管死亡复合结局的效应(校正交互作用P分别为.03和.01)。
- 其他结局未见效应;连续TSH分析或排除TSH异常或使用甲状腺药物者后结果相似。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 作者指出这些发现应视为探索性,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Subclinical thyroid dysfunction is a marker for atrial fibrillation (AF) and stroke risk. OBJECTIVE: This study explored the effects of AF screening according to thyroid-stimulating hormone (TSH) levels. METHODS: An AF screening trial (the LOOP study) was analyzed post hoc according to baseline TSH. The primary outcome was stroke or systemic embolism (SE). Secondary outcomes included major bleeding, all-cause death, and the combination of stroke, SE, and cardiovascular death. RESULTS: TSH measurements were available in 6003 of 6004 trial participants, 1500 randomized to implantable loop recorder (ILR) screening for AF and anticoagulation upon detection vs 4503 to usual care; mean age was 74.7 ± 4.1 years and 2836 (47%) were women. AF detection was approximately triple for ILR vs usual care across TSH tertiles (adjusted P interaction = 0.44). In the first tertile, screening was associated with decreased risk of the primary outcome (hazard ratio [HR] 0.52, 95% CI 0.30-0.90; P = .02) and stroke, SE, or cardiovascular death (HR 0.54, 95% CI 0.34-0.84; P = .006) compared with usual care, while no effect was observed among participants with higher TSH (adjusted P interaction .03 and .01, respectively). There was no effect on other outcomes. Analyses of continuous TSH or excluding those with abnormal TSH or thyroid medication showed similar results. CONCLUSION: AF screening and subsequent treatment was associated with decreased stroke risk among participants with low TSH, though the yield of screening was similar across TSH levels. TSH may be useful as a marker to indicate benefit from AF screening vs overdiagnosis and overtreatment. These findings should be considered exploratory and warrant further study.
引用
- Spona DC, Frodi DM, Xing LY, et al. Effects of Atrial Fibrillation Screening According to Thyroid Function: Post Hoc Analysis of the Randomized LOOP Study. J Clin Endocrinol Metab. 2025. PMID: 39231015. doi:10.1210/clinem/dgae610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。